CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report
- SKU ID : TNV-IRTNTR15822 11170897
- |
- Publishing Date: 13-Oct-2017
- |
- Region: Global
- |
- No. of pages: 70
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma: An insight
The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.
Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.
In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.
According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.
Covered in this report
The report covers the present scenario and the growth prospects of the car T-cell therapy for multiple myeloma. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
Major companies
• Juno Therapeutics
• Kite Pharma
• Novartis
• Collectis
Key questions answered in this report
• How will the market evolve during the forecast period?
• What are the major parameters impacting the market?
• What are the key market trends?
• What are the challenges to market growth?
• Who are the key companies in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.
Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.
In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.
According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.
Covered in this report
The report covers the present scenario and the growth prospects of the car T-cell therapy for multiple myeloma. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
Major companies
• Juno Therapeutics
• Kite Pharma
• Novartis
• Collectis
Key questions answered in this report
• How will the market evolve during the forecast period?
• What are the major parameters impacting the market?
• What are the key market trends?
• What are the challenges to market growth?
• Who are the key companies in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
